

Evonik.
Power to create.

Company presentation

December 2015



EVONIK
INDUSTRIES

Table of contents



1	Evonik at a glance
2	Group strategy
3	Financials Q3 2015
4	Appendix

One of the world leaders in specialty chemicals



19.1%

adj. EBITDA margin in
first nine month of 2015

~2,000

marketing and sales
experts globally

80%

of sales from
#1-3 market positions

~33,000

employees in more
than 100 countries

>4%

average volume growth
(CAGR) since 2009¹

~500

R&D projects driving
innovation

¹ Excluding Carbon Black and Real Estate

Three specialty chemicals segments



Sales
€12,917 m

Adj. EBITDA
€1,882 m

Margin
14.6%

ROCE
12.5%



Nutrition & Care

Products for applications in the consumer goods, animal nutrition and healthcare sectors

Sales €4,075 m
Adj. EBITDA €847 m
Margin 20.8%



Resource Efficiency

Environment-friendly and energy-efficient system solutions

Sales €4,040 m
Adj. EBITDA €836 m
Margin 20.7%



Performance Materials

Polymer materials and intermediates mainly for the rubber and plastics industries

Sales €3,827 m
Adj. EBITDA €325 m
Margin 8.5%

Services

Sales
Adj. EBITDA

€906 m
€151 m


Corporate / Other

Sales
Adj. EBITDA

€69 m
- €277 m


Balanced and diversified portfolio

End market split¹



No dependency on single end markets;
no end market exposure >20%

Sales by region²



Strong European heritage,
selected expansion into growth regions

¹ Based on specialty chemicals segments' 2014 sales

² Consolidated Group sales 2014

Committed to create value




Table of contents



1	Evonik at a glance
2	Group strategy
3	Financials Q3 2015
4	Appendix

New corporate structure

Enabling differentiated management of segments



Strategic Management Holding

- Three specialty chemicals segments **as separate legal entities**
- **Differentiated management of businesses** tailored to specific needs
- **Higher degree of entrepreneurial freedom**

Nutrition & Care

Resource Efficiency

Performance Materials



Investments



Innovation



M&A



Levers for sustainable growth

Combining internal and external growth

Investments



- Focused investments into high-growth end markets and regions
- Disciplined and flexible approach in execution
- Recently finished projects according with increasing earnings contribution

Innovation



- “Power to create” as part of Evonik’s DNA
- “Leading innovation” initiative with ambition to generate best-in-class ideas for future products and solutions
- Strong market and customer orientation for tailor-made solutions

M&A



- Acquisitions as additional route for value creation
- Sharpening of specialty chemicals portfolio
- Proven track record of portfolio optimization
- Disciplined use of funds

Investments

Major projects finished in 2014, more underway

Plants in planning or construction phase

Fumed silica & silanes platform

Capex ~€100 m
Start up 2017

New silica plant


Capex >€50 m
Start up 2017

Silicone platform

Capex >€100 m
Start up 2017

New silica plant

Capex ~€50 m
Start up 2016



Recently finished investment projects



Expansion C4 chain

Capex >€250 m
Start up mid 2015



Isophorone chain

Capex >€100 m
Start up Q2 2014



Oleochemicals plants

Capex >€100 m
China: Start up Q4 2013
Brazil: Start up Q1 2015



Methionine plant

Capex >€500 m
Start up Q4 2014




● Nutrition & Care ● Resource Efficiency ● Performance Materials


Investments

Capex returning to sustainable level after 2016

Capex spending (in € m)



Growth capex by segment and region¹




¹ After 2016

Innovation

Strong market and customer orientation

Transformational innovation (Creavis)

- Centralized, mid-to-long-term R&D



Core and adjacent business innovation

- Decentralized, shorter-term R&D in operating segments
- Cross business, e.g. in industry teams
- Very close to customers (often joint R&D efforts)

Technology /
Products

new
adjacent
established

Transformational innovation

Adjacent business innovation

Incremental core business innovation

established

adjacent

new

Market /
Application

¹ R&D expenses 2014 (vs. 2013)

Semi-conductors for high-resolution screens



- Inorganic metal-oxide semi-conductors replacing traditional amorphous silicon
- Enabling higher image resolution of ultra-HD televisions
- Significant production process simplification
- After successful customer trials in early 2015, product rollout together with strategic partners starting now


Algae-based omega-3 fatty acids



- Joint development agreement for algae-based omega-3 fatty acid products for animal nutrition with DSM
- Currently, more fish is used as feed than the final aquacultured fish production delivers
→ Need for a more sustainable route to fish farming
- Solution are amino acids to reduce the fishmeal content in fish diets and a source of highly unsaturated algal omega-3 product to reduce fish oil content in diets

Proven history of efficiency improvements

Improving cost position since 2009



**Aspiration level: Adj. EBITDA of >€3 bn
and an attractive premium on cost of capital**




Table of contents



1	Evonik at a glance
2	Group strategy
3	Financials Q3 2015
4	Appendix

Highlights Q3 2015

Evonik delivers third strong quarter in a row



Strong operational performance

Strong business performance continued into H2

Adj. EBITDA of €653 m clearly above prior year (+31%), year-on-year earnings growth in all three chemical segments

Outlook confirmed: adj. EBITDA of around €2.4 bn expected for FY 2015

Consistent execution of strategy

New **world-scale methionine complex in Singapore** planned for 2019 to meet strong demand for sustainable animal nutrition



Acquisition of hydrogen peroxide plant in the Netherlands to complement our European asset footprint



Financial highlights Q3 2015

Adj. EBITDA margin climbing to 19.4%



Sales increased by 4% to €3,365 m supported by positive price development, volumes impacted by planned maintenance shutdowns

Adj. EBITDA of €653 m in line with the previous quarters' high levels

Adj. EBITDA margin of 19.4% stands out within the chemicals sector


Strong **operating cash flow** generation of €717 m (prior year: €312 m); net cash position increased to €963 m

Financial highlights Q3 2015


Positive price development; volumes impacted by planned maintenance shutdowns




Sales (in € m)




Adj. EBITDA (in € m) / margin



Adj. EPS (in €)



Net financial position (in € m)



Nutrition & Care

Another excellent quarter for Animal Nutrition

Sales (in € m)

Q3 15 vs. Q3 14

Volume

+1% ↗

Price


+16% ↗

FX



+5% ↗

Other

0% →




Adj. EBITDA (in € m) / margin (in %)







Resource Efficiency

Sales and earnings up yoy despite maintenance


Sales (in € m)



Q3 15 vs. Q3 14

Volume	Price
-3% 	+1% 
FX	Other
+3% 	+1% 


Adj. EBITDA (in € m) / margin (in %)



Performance Materials

Temporary margin improvement in C4 business

Sales (in € m)



Q3 15 vs. Q3 14

Volume

-2% ↓

Price

-11% ↓


FX

+2% ↑

Other

0% →

Adj. EBITDA (in € m) / margin (in %)




Cash flow development

Strong operating cash flow generation



Development of net financial position (in € m)




¹ Cash outflow for investment in intangible assets, PP&E and shareholdings, not including cash in- and outflows related to divestments and securities
December 2015 | Evonik company presentation | Financials Q3 2015

Cash flow development


OCF significantly above prior year already after nine months; FCF turning positive




Operating Cash Flow (cont. op. in € m)



Investing Cash Flow (cont. op. in € m)¹



Free Cash Flow (cont. op. in € m) (before dividends and divestments)



¹ Cash outflow for investment in intangible assets, PP&E and shareholdings, not including cash in- and outflows related to divestments and securities
December 2015 | Evonik company presentation | Financials Q3 2015

Outlook for 2015 confirmed

Adj. EBITDA of around €2.4 bn expected



Outlook FY 2015:

Sales: ~ €13.5 bn

Adj. EBITDA: around €2.4 bn

Growth investments

Efficiency measures

Operational performance

FY 2014:

Sales: €12.9 bn

Adj. EBITDA: €1.9 bn

Positive FX impact on sales and adj. EBITDA included in outlook (assumption: US\$1.13)

Effects from lower raw material prices should largely balance out on Group level

December 2015 | Evonik company presentation | Financials Q3 2015

Additional indications for 2015

- EUR/USD sensitivity¹ +/-1 USD cent = -/+ ~€5 m adj. EBITDA (FY basis)
- Adj. EBITDA Services **Slightly below 2014** (*unchanged*; 2014: €151 m)
- Adj. EBITDA Corporate/Other **More negative than -€300 m** (*unchanged*; 2014: -€277 m)
- Adj. D&A ~ **-€700 m** (*unchanged*; 2014: -€626 m)
- Adj. net financial result² **Slight improvement** (*unchanged*; 2014: -€209 m)
- Adj. tax rate ~**29%** (*unchanged*; 2014: 28.3%)
- Capex **Up to €1.1 bn** in 2015 (*unchanged*; 2014: €1.1 bn)
- Net financial position **Net cash position of more than €800 m**, including €200 m contribution to CTA in Q4 (*previously: “net cash position of more than €500 m”; 2014: €400 m net cash*)

¹ Including transaction effects (after hedging) and translation effects; before secondary / market effects

² Guidance for “Adj. net financial result” (incl. “Adj. interest income/expense” and “Other financial income/expense”)



EVONIK
INDUSTRIES

Table of contents



A	Financial policy and pensions
B	Company history and ownership structure
C	Specialty chemicals segments
D	Upcoming IR events and contact

Financial policy

**Maintaining a
solid investment grade rating**

Goal: Evonik as a long-term reliable partner of bond investors and banks



Financing structure

- Equity ratio 42%
- Net financial position of €963 m
- Balanced debt maturity profile


Strong balance sheet and financing structure



Balanced maturity profile

No major maturities until 2020

Maturity profile (in € m)




- Maturity of syndicated revolving credit facility (RCF) extended by one year to 2018/20 (€875 m each)
- Repayment of €750 m 7% bond (2009/14) in October 2014
- Issuance of new €750 m 1% bond in January 2015 (8yrs to 2023); achieved lowest ever 8-year spread and coupon for a BBB (+/-/flat) rated corporate issuer
- No major maturities until 2020

Rating history

Positioned in upper range of BBB

Rating development




- S&P's rating BBB+ with stable outlook since May 2012
 - Moody's rating Baa2 with positive outlook since March 2014
 - Impressive rating dynamic thanks to focus on specialty chemicals and clear financial policy
- ▼
- **Maintaining a solid, long-term investment grade rating is an integral part of our financial policy**

Pensions

Pension obligations well financed

Pension funding overview as of Dec 31, 2014



- Pensions very long-term, patient debt with no funding obligations in Germany
- Funding ratio remains on solid level above 60%
- Further cash contribution of €200 m intended in Q4 2015 (ends cash contribution plan of €1.6 bn from 2010-2015)
- Corresponding deferred tax assets of about €1 bn

Pensions

Breakdown of P&L and cash flow effects

P&L

in € m	P&L item / KPI	2013	2014	Annual report
Current service costs	Adj. EBITDA	-178	-172	p. 223
Interest costs	Net interest expense	-330	-341	p. 220
Exp. return on plan assets	Net interest expense	+195	+224	p. 221
Other	Adj. EBITDA	-50	-38	p. 223
Total pension expense		-363	-327	

Cash flow

in € m		2013	2014	Annual report
Benefits paid	} From defined benefit plans	-401	-404	p. 220
Benefits paid from plan assets		+168	+163	p. 221
Contribution to plan assets (excl. CTA)		-126	-135	p. 221
Payments under defined contribution plans		-134	-144	p. 223
Total cash out for pensions (excl. CTA)		-493	-520	

Pensions

Discount rate changes with significant effects on balance sheet and P&L

Sensitivity analysis¹:
Increase (decrease) in
discount rate
by 100 bp in year x

Impact in year x

- **Personnel costs:** no impact
- **Finance costs:** no impact
- **Cash flow:** no impact
- **Balance sheet:** decrease (increase) of pension provision by -€1.5 bn (+€2.0 bn) against equity and deferred tax liabilities (assets)

Impact in year x+1

- **Personnel costs:** decrease (increase) due to lower (higher) service costs
- **Finance costs:** increase (decrease) due to higher (lower) pension interest
- **Cash flow:** no impact
- **Balance sheet:** no impact


¹ Excluding any effects from potential actuarial changes

Net debt development

Increase in pension obligations in Q3 due to slightly lower discount rate



Net debt development (in € m)



- Majority of debt consists of long-dated pension obligations; average life of DBO exceeds 15 years
- Increase of unfunded pension obligations in Q3 by about €300 m due to slightly lower discount rate (from 2.75% to 2.50% in Germany)

2013	2014	Q1 2015	Q2 2015	Q3 2015	Evonik Group global discount rate ² Evonik discount rate for Germany
3.84	2.65				
3.75	2.50	1.75	2.75	2.50	

¹ Total leverage defined as (net financial debt + pension provisions) / adj. EBITDA LTM


² Calculated annually

Dividend policy

Reliability and attractive returns



Dividend history (in €)



Dividend policy


Two components of Evonik's dividend policy:

- 1) Overarching target of **dividend continuity**
 - 2) additionally, targeted payout ratio: **~40% of adjusted net income**
- Compelling track record with regards to dividend policy and shareholder returns (already pre-listing)
 - Dividend for 2014 of 1.00 €; stable dividend despite lower adj. net income


Strong financial track record

Sales (in € m)


Carbon Black/Real Estate




Adj. EBITDA (in € m) / margin¹



Adj. net income (in € m)




ROCE (in %)



¹ Excluding Carbon Black

Raw material split

Total procurement volume 2014 (in € m)



Oil price link of raw material spend¹ (examples)

- Sodium silicate (Silica)
- Sugar (Animal Nutrition)
- Fatty acids (Personal Care)

No oil price link

Direct oil price link

- CC4 (Performance Intermediates)
- Propylene (Baby Care, Animal Nutrition)

Indirect oil price link

- Acrylic acid (Baby Care)
- Acetone (Coatings & Additives, Acrylic Monomers)
- Methanol (Acrylic Monomers, Performance Intermediates)

¹ Raw material spend ~60% of total procurement volume in 2014
December 2015 | Evonik company presentation | Appendix

Table of contents



A	Financial policy and pensions
B	Company history and ownership structure
C	Specialty chemicals segments
D	Upcoming IR events and contact


Company history

More than 150 years of experience in chemicals



Ownership structure

- **RAG-Stiftung:** Obligation to finance the perpetual liabilities arising from the cessation of hard-coal mining in Germany; intention to retain a strategic shareholding of **at least 25.1% in the long term**



Presence on capital markets

- Trading since April 25, 2013 in the Prime Standard of Frankfurt Stock Exchange
- 14.2% of Evonik shares successfully placed in advance of the listing (7.1% by RAG-Stiftung and CVC¹ each)
- CVC sold additional 13.7% of shares in four tranches between March and November 2015
- CVC currently holds 4.2% of shares, which are the basis and collateral for an exchangeable bond
- **Free Float market cap ~€5 billion**
- Average **daily trading volume > €15 million** per day (>600 k shares)

¹ Shares held by Gabriel Acquisitions GmbH, an indirect subsidiary of funds advised by CVC

Management compensation (as of 2014)

Value creation focus anchored in management incentivization system at Board level



Fixed salary (c.30%)	<ul style="list-style-type: none">• To be paid in cash for each financial year on a monthly basis
Bonus (c.33%)	<ul style="list-style-type: none">• To be paid out in cash annually• Pay-out calculated on the basis of the achievement of certain, primarily value creation focused KPIs (e.g. ROCE, adj. net income, adj. EBITDA) and accident performance• Factor of between 0.8 and 1.2 to take into account the achievement of further individual targets• Bonus capped at 200% of initial target
Long term incentive plan (c.37%)	<ul style="list-style-type: none">• Granted LTI target amount is calculated in virtual shares (4-year lock-up)• Value of LTI to mirror the development of Evonik's share price (incl. dividends)• Amount payable is determined by two performance elements:• Absolute performance: Real price of the Evonik share• Relative performance against external index benchmark (MSCI Chemicals)• Bonus capped at 300% of initial amount• To be paid out in cash after lock-up period

Table of contents



A	Financial policy and pensions
B	Company history and ownership structure
C	Specialty chemicals segments
D	Upcoming IR events and contact

Specialty Chemicals segments

New segment structure from January 2015

Segments	Nutrition & Care 		Resource Efficiency 		Performance Materials 	
	KPI's		KPI's		KPI's	
	Sales: €4,075 m Adj. EBITDA: €847 m Adj. EBITDA margin: 20.8%		Sales: €4,040 m Adj. EBITDA: €836 m Adj. EBITDA margin: 20.7%		Sales: €3,827 m Adj. EBITDA: €325 m Adj. EBITDA margin: 8.5%	
Business Lines	Animal Nutrition (~35%)	Health Care (~10%)	Silica (~25%)	Coating & Adhesive Resins (~10%)	Performance Intermediates (~45%)	Agrochemicals (~5%)
	Baby Care (~25%)	Comfort & Insulation (~5%)	Oil Additives (~15%)	Silanes (~10%)	Acrylic Monomers (~20%)	Functional Solutions (~5%)
	Personal Care (~10%)	Interface & Performance (~5%)	Crosslinkers (~10%)	Coating Additives (~5%)	Acrylic Polymers (~20%)	CyPlus Technologies (~5%)
	Household Care (~10%)		Active Oxygens (~10%)	Catalysts (~5%)		
			High Performance Polymers (~10%)			

Financials for FY 2014, restated to reflect new segment structure from Jan 1st, 2015

Nutrition & Care

Business Line overview (1/2)

Key products
Main Applications
Market position¹
Main competitors

Animal Nutrition



- Methionine
- Lysine, Threonine, Tryptophan

- Feed additives and services for animal nutrition

- # 1 in Feed Amino Acids

- Chem China/Adisseo
- Novus
- Ajinomoto
- Cheil Jedang

Baby Care



- Superabsorbents

- Baby Care
- Female Care
- Adult Care

- # 2-3 in superabsorbents

- BASF
- Nippon Shokubai

Personal Care



- Actives
- Emulsifiers
- Conditioners

- Personal Care

- # 4 in cosmetic ingredients

- Ashland
- BASF
- Croda

Household Care



- Fabric conditioners
- Specialty surfactants

- Laundry care
- Home care
- Car care

- # 1 in fabric softeners

- AkzoNobel
- BASF
- Solvay
- Stepan

¹ Company estimates for relevant markets based on multiple research reports

Nutrition & Care

Business Line overview (2/2)

Key products
Main Applications
Market position¹
Main competitors

Health Care




- Active pharma ingredients
- Pharma grade amino acids
- Pharmaceutical coatings

- Drug delivery systems for oral and parenteral dosage
- Tailor-made pharmaceutical syntheses
- Pharma Amino Acids

- # 1 Functional Polymers for Controlled Release
- # 2 Exclusive Synthesis
- # 3 Pharma Amino Acids

- BASF
- DSM
- Lonza
- Ajinomoto

Comfort & Insulation



- Foam stabilizers
- Catalysts
- Release agents

- Furniture / appliances
- Construction
- Automotive

- # 1 in polyurethane foam additives

- Air Products
- Maysta
- Momentive

Interface & Performance



- Release coatings
- Super spreading additives

- Packaging / tapes
- Agrochemicals
- Plastic additives

- # 1-2 in release coatings

- Clariant
- Dow Corning
- Momentive
- Wacker

¹ Company estimates for relevant markets based on multiple research reports

Resource Efficiency

Business Line overview (1/3)

Key products
Main Applications
Market position¹
Main competitors

Silica



- Precipitated silica
- Fumed silica
- Special oxides

- Silicone rubber
- Tires, green tires & rubber
- Paints & coatings
- Adhesives & sealants

- # 1 in silicas (precipitated, fumed, special oxides, matting agents and specialty fillers)

- Cabot
- JM Huber
- Solvay
- Wacker

Oil Additives



- Lubricant additives (viscosity modifiers)
- Fuel additives

- Auto & industrials
- Hydraulic systems
- Refinery processing
- Biofuels

- # 1 in viscosity modifiers for lubricants

- Infineum
- Lubrizol
- NewMarket (Afton)
- Oronite

Crosslinkers



- Crosslinkers for composites, elastomers and non-solvent coatings

- Composites
- Coatings & paints
- Flooring
- Automotive interior

- # 1 in isophorone chemicals

- Arkema
- BASF
- Bayer

¹ Company estimates for relevant markets based on multiple research reports

Resource Efficiency

Business Line overview (2/3)

Key products
Main Applications
Market position¹
Main competitors

Active Oxygens



- Hydrogen peroxide

- Oxidising agent in chemical reactions
- Pulp & paper bleaching

- # 2 in hydrogen peroxide

- Arkema
- Solvay

High Performance Polymers



- High perf. polyamide (PA12)
- Polyetheretherketone (PEEK)
- Membranes and Polyimide fibres

- Automotive components
- Medical
- Oil & gas pipes

- # 1 in PA12

- Arkema
- EMS
- Solvay
- Victrex

Coating & Adhesive Resins



- Functional resins
- Adhesive hot melts
- Heat sealants
- Polybutadiene

- Hot melt
- Pre coated metal
- Protective coatings
- Road marking

- # 1 in polyester resins

- Dow
- DSM
- Mitsubishi Chemical

¹ Company estimates for relevant markets based on multiple research reports

Resource Efficiency

Business Line overview (3/3)

Key
products

Silanes



- Chlorosilanes
- Organofunctional silanes
- Rubber silanes

Main
Applications

- Fumed silica
- Optical fibres
- Adhesive & sealants
- Building protection

Market
position¹

- # 1 in chlorosilanes
- # 1 in organofunctional and rubber silanes

Main
competitors

- Dow Corning
- Momentive
- Shin Etsu
- Tokuyama

Coating Additives



- Additives for eco-friendly and highly solid industrial coatings

- Eco-friendly coatings (low VOC, water based)
- High solid industrial coatings

- # 2 in high performance additives for coatings and inks
- # 1-2 in silicone resins for special applications

- Altana
- BASF
- Dow Corning

Catalysts



- Activated base metal catalysts
- Precious metal catalysts
- Catalysts for industrial & petrochemicals

- Catalysts for chemical processes
- Enabler for process efficiency / innovation

- #1 in precious metal powder catalysts
- #3 in activated base metal catalysts

- BASF
- Clariant
- Johnson Matthey
- WR Grace

¹ Company estimates for relevant markets based on multiple research reports

Performance Materials

Business Line overview (1/2)

Key products
Main Applications
Market position¹
Main competitors

Performance Intermediates



- Butadiene
 - MTBE
 - Butene-1
 - Plasticizers (INA&DINP)
-
- Plastics
 - Styrene-Butadiene-Rubber
 - High performance polymers
-
- # 1 in butene-1
-
- BASF
 - Sabic
 - LyondellBasell

Acrylic Monomers



- Methylmethacrylate (MMA) & application monomers
 - Methacrylic acid
-
- Coatings
 - PMMA
 - Monomers for specialty applications
-
- # 2 in MMA
-
- LG MMA
 - Mitsubishi Chemicals
 - Sumitomo

Acrylic Polymers



- Molding compounds
 - Acrylic sheets (Plexiglas / Acrylite)
 - PMMA systems
-
- LED/touch screens
 - Construction
 - Light-weight systems
 - Automotive components
-
- # 1-2 in PMMA
-
- Arkema
 - Mitsubishi Chemicals
 - Sumitomo

¹ Company estimates for relevant markets based on multiple research reports

Performance Materials

Business Line overview (2/2)

Key products
Main Applications
Market position¹
Main competitors

Agrochemicals



- Triacetoneamine
- Crosslinkers
- Precursors of glyphosates

- Polymer additives
- Optical brighteners
- Photovoltaic
- Agro chemicals

- n.a.

- Lanxess
- Weylchem

Functional Solutions



- Alkoxides
(e.g. sodium methyllate)

- Catalysts for biodiesel production

- # 1 in alkoxides

- BASF
- DuPont

CyPlus Technologies



- Sodium cyanide
- Potassium cyanide

- Precious metals mining
- Fine chemicals

- n.a.

- AGR
- DuPont
- Orica

¹ Company estimates for relevant markets based on multiple research reports

Table of contents



A	Financial policy and pensions
B	Company history and ownership structure
C	Specialty chemicals segments
D	Upcoming IR events and contact

Upcoming IR events

Roadshows

- 3 December, 2015: Edinburgh
- 4 December, 2015: Dublin
- 18 December, 2015: London

Conference participations

- 2 December, 2015: BoAML European Chemicals Conference, London

Next reporting dates

- 3 March, 2016: Q4 / FY 2015 reporting



**Please find an updated schedule
on our IR website
("Events & Presentations")**

Evonik Investor Relations team



Tim Lange

Head of Investor Relations

+49 201 177 3150

tim.lange@evonik.com



Janine Kanotowsky

Team Assistant

+49 201 177 3146

janine.kanotowsky@evonik.com



Kai Kirchhoff

Investor Relations Manager

+49 201 177 3145

kai.kirchhoff@evonik.com



Dr. Friederike Molls

Investor Relations Manager

+49 201 177 3147

friederike.molls@evonik.com



Christoph Rump

Investor Relations Manager

+49 201 177 3149

christoph.rump@evonik.com

Disclaimer

In so far as forecasts or expectations are expressed in this presentation or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.



EVONIK
INDUSTRIES